<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02412761</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-13-0287</org_study_id>
    <secondary_id>5KL2TR000370</secondary_id>
    <nct_id>NCT02412761</nct_id>
  </id_info>
  <brief_title>Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension</brief_title>
  <official_title>Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children are increasingly being diagnosed with essential hypertension and the absence of
      comparative effectiveness research in antihypertensive therapies has contributed to
      considerable differences in prescribing practices among physicians treating children with
      essential hypertension.

      This study will consist of a series of systematically-administered n-of-1 trials among
      children to verify the need for ongoing antihypertensive treatment and if so, to identify the
      preferred single drug therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a series of systematically-administered n-of-1 trials among children with essential
      hypertension to verify the need for ongoing antihypertensive treatment and if so, to identify
      the preferred single drug therapy from among the three major classes of drugs commonly used
      for essential hypertension (angiotensin converting enzyme inhibitors, calcium channel
      blockers, and diuretics). The investigators will determine whether there is one that is
      preferred for the great majority of patients. The &quot;preferred&quot; therapy will be defined as the
      drug which produces normal ambulatory blood pressure, with the greatest reduction in awake
      mean systolic blood pressure without unacceptable side effects.

      For each patient, the order of the 3 drugs will be assigned randomly and each drug will be
      taken for 2 weeks. The effectiveness of each drug will be measured with 24-hour ambulatory
      blood pressure monitoring, and tolerability will be assessed using a side effect
      questionnaire. Participants will rotate through treatment periods, repeating drugs and
      adjusting doses until the preferred therapy is identified. In assessing whether one the
      medications is most effective for the great majority of subjects, the primary outcome will be
      the percentage of participants for whom each drug is selected as the preferred therapy.
      Primary hypothesis: no drug will be selected for the majority of the subjects, a finding that
      would support consideration of clinical use of n-of-1 trials. Secondary analyses will explore
      whether patient characteristics predict which medication will be selected as a preferred
      drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Patients for Whom Each Drug is Selected as the Preferred Therapy</measure>
    <time_frame>The outcome of BP control and side effect tolerability will be assessed 2 weeks after starting each drug. Participants will be followed for an average of 10-12 weeks.</time_frame>
    <description>For each n-of-1 trial, the preferred drug is defined as that which produces normal ambulatory blood pressure (by pediatric Ambulatory blood pressure monitoring (ABPM) standards), with the greatest magnitude of wake mean systolic BP reduction, and without unacceptable side effects.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Amlodipine, then HCTZ, then Lisinopril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants first received amlodipine once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine, then Lisinopril, then HCTZ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants first received amlodipine once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCTZ, then Amlodipine, then Lisinopril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCTZ, then Lisinopril, then Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lisinopril, then Amlodipine, then HCTZ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants first received lisinopril once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lisinopril, then HCTZ, then Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants first received lisinopril once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <description>Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.</description>
    <arm_group_label>Amlodipine, then HCTZ, then Lisinopril</arm_group_label>
    <arm_group_label>Amlodipine, then Lisinopril, then HCTZ</arm_group_label>
    <arm_group_label>HCTZ, then Amlodipine, then Lisinopril</arm_group_label>
    <arm_group_label>HCTZ, then Lisinopril, then Amlodipine</arm_group_label>
    <arm_group_label>Lisinopril, then Amlodipine, then HCTZ</arm_group_label>
    <arm_group_label>Lisinopril, then HCTZ, then Amlodipine</arm_group_label>
    <other_name>Angiotensin-converting enzyme inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose</description>
    <arm_group_label>Amlodipine, then HCTZ, then Lisinopril</arm_group_label>
    <arm_group_label>Amlodipine, then Lisinopril, then HCTZ</arm_group_label>
    <arm_group_label>HCTZ, then Amlodipine, then Lisinopril</arm_group_label>
    <arm_group_label>HCTZ, then Lisinopril, then Amlodipine</arm_group_label>
    <arm_group_label>Lisinopril, then Amlodipine, then HCTZ</arm_group_label>
    <arm_group_label>Lisinopril, then HCTZ, then Amlodipine</arm_group_label>
    <other_name>Dihydropyridine calcium channel blocker</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose</description>
    <arm_group_label>Amlodipine, then HCTZ, then Lisinopril</arm_group_label>
    <arm_group_label>Amlodipine, then Lisinopril, then HCTZ</arm_group_label>
    <arm_group_label>HCTZ, then Amlodipine, then Lisinopril</arm_group_label>
    <arm_group_label>HCTZ, then Lisinopril, then Amlodipine</arm_group_label>
    <arm_group_label>Lisinopril, then Amlodipine, then HCTZ</arm_group_label>
    <arm_group_label>Lisinopril, then HCTZ, then Amlodipine</arm_group_label>
    <other_name>Thiazide diuretic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of essential hypertension

          -  Treating physician has determined that pharmacologic therapy is necessary

        Exclusion Criteria:

          -  Compelling indication to select one particular medication

          -  Specific contraindication for any of the 3 therapies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joyce P Samuel, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas at Houston Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas at Houston Medical School; Pediatric Nephrology and Hypertension Clinics</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Samuel JP, Samuels JA, Brooks LE, Bell CS, Pedroza C, Molony DA, Tyson JE. Comparative effectiveness of antihypertensive treatment for older children with primary hypertension: study protocol for a series of n-of-1 randomized trials. Trials. 2016 Jan 8;17:16. doi: 10.1186/s13063-015-1142-y.</citation>
    <PMID>26746195</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>April 3, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <results_first_submitted>May 1, 2018</results_first_submitted>
  <results_first_submitted_qc>November 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 15, 2018</results_first_posted>
  <last_update_submitted>November 9, 2018</last_update_submitted>
  <last_update_submitted_qc>November 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Joyce Philip Samuel</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Anti-hypertensive medications</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>N-of-1 trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Sodium Chloride Symporter Inhibitors</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From June 2013 until July 2016, 55 patients were eligible based on inclusion/exclusion criteria, and 42/55 patients (76%) agreed to participate.</recruitment_details>
      <pre_assignment_details>Forty-two children agreed to participate. Among the 30 patients taking antihypertensive medication prior to enrollment, 20 completed an updated baseline ambulatory BP monitoring. As a result, 23% (7/30) were found to be normotensive without medication, and did not undergo an n-of-1 trial. These 7 patients were not assigned to a treatment arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Amlodipine, Then HCTZ, Then Lisinopril</title>
          <description>Participants first received amlodipine once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response</description>
        </group>
        <group group_id="P2">
          <title>Amlodipine, Then Lisinopril, Then HCTZ</title>
          <description>Participants first received amlodipine once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.</description>
        </group>
        <group group_id="P3">
          <title>HCTZ, Then Amlodipine, Then Lisinopril</title>
          <description>Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.</description>
        </group>
        <group group_id="P4">
          <title>HCTZ, Then Lisinopril, Then Amlodipine</title>
          <description>Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.</description>
        </group>
        <group group_id="P5">
          <title>Lisinopril, Then Amlodipine, Then HCTZ</title>
          <description>Participants first received lisinopril once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.</description>
        </group>
        <group group_id="P6">
          <title>Lisinopril, Then HCTZ, Then Amlodipine</title>
          <description>Participants first received lisinopril once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects who participated in an n-of-1 trial received all three interventions in a cross-over fashion.</population>
      <group_list>
        <group group_id="B1">
          <title>Participants Who Completed N-of-1 Trials</title>
          <description>Participants who completed the first treatment cycle in the n-of-1 trial</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14" lower_limit="9" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Patients for Whom Each Drug is Selected as the Preferred Therapy</title>
        <description>For each n-of-1 trial, the preferred drug is defined as that which produces normal ambulatory blood pressure (by pediatric Ambulatory blood pressure monitoring (ABPM) standards), with the greatest magnitude of wake mean systolic BP reduction, and without unacceptable side effects.</description>
        <time_frame>The outcome of BP control and side effect tolerability will be assessed 2 weeks after starting each drug. Participants will be followed for an average of 10-12 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril</title>
            <description>Lisinopril: Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>Amlodipine: Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose</description>
          </group>
          <group group_id="O3">
            <title>Hydrochlorothiazide</title>
            <description>Hydrochlorothiazide: Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients for Whom Each Drug is Selected as the Preferred Therapy</title>
          <description>For each n-of-1 trial, the preferred drug is defined as that which produces normal ambulatory blood pressure (by pediatric Ambulatory blood pressure monitoring (ABPM) standards), with the greatest magnitude of wake mean systolic BP reduction, and without unacceptable side effects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lisinopril</title>
          <description>Lisinopril: Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.</description>
        </group>
        <group group_id="E2">
          <title>Amlodipine</title>
          <description>Amlodipine: Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose</description>
        </group>
        <group group_id="E3">
          <title>Hydrochlorothiazide</title>
          <description>Hydrochlorothiazide: Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joyce P. Samuel, MD, MS</name_or_title>
      <organization>The University of Texas Health Science Center at Houston</organization>
      <phone>(713) 500-5670</phone>
      <email>Joyce.P.Samuel@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

